Read by QxMD icon Read

Predictor died for MDR TB

Noorsuzana Mohd Shariff, Shamsul Azhar Shah, Fadzilah Kamaludin
The emergence of drug-resistant tuberculosis (TB) is a major public health threat. However, little is known about the predictors of death in drug-resistant TB in Malaysia. This study aimed to determine the predictors of death in drug-resistant TB patients, including multidrug-resistant TB (MDR-TB), in Kuala Lumpur, Malaysia. This study adopted a retrospective cohort study design and involved laboratory-confirmed drug-resistant TB patients (n=426) from January 2009 to June 2013. A Cox regression model and Kaplan-Meier curves were used to model the outcome measure...
September 2016: Journal of Global Antimicrobial Resistance
Silvia S Chiang, Jeffrey R Starke, Ann C Miller, Andrea T Cruz, Hernán Del Castillo, William José Valdivia, Gabriela Tunque, Fanny García, Carmen Contreras, Leonid Lecca, Valentina A Alarcón, Mercedes C Becerra
BACKGROUND: Globally, >30 000 children fall sick with multidrug-resistant (MDR) tuberculosis every year. Without robust pediatric data, clinical management follows international guidelines that are based on studies in adults and expert opinion. We aimed to identify baseline predictors of death, treatment failure, and loss to follow-up among children with MDR tuberculosis disease treated with regimens tailored to their drug susceptibility test (DST) result or to the DST result of a source case...
October 15, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Rebecca C Harris, Louis Grandjean, Laura J Martin, Alexander J P Miller, Joseph-Egre N Nkang, Victoria Allen, Mishal S Khan, Katherine Fielding, David A J Moore
BACKGROUND: Globally it is estimated that 480 000 people developed multidrug-resistant tuberculosis (MDR-TB) in 2014 and 190 000 people died from the disease. Successful treatment outcomes are achieved in only 50 % of patients with MDR-TB, compared to 86 % for drug susceptible disease. It is widely held that delay in time to initiation of treatment for MDR-TB is an important predictor of treatment outcome. The objective of this review was to assess the existing evidence on the outcomes of multidrug- and extensively drug-resistant tuberculosis patients treated early (≤4 weeks) versus late (>4 weeks) after diagnosis of drug resistance...
2016: BMC Infectious Diseases
Naira Dekhil, Nedra Meftahi, Besma Mhenni, Saloua Ben Fraj, Raja Haltiti, Sameh Belhaj, Helmi Mardassi
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) outbreaks that evolve, from the outset, in a context strictly negative for HIV infection deserve special consideration since they reflect the true intrinsic epidemic potential of the causative strain. To our knowledge, the long-term evolution of such exceptional outbreaks and the treatment outcomes for the involved patients has never been reported hitherto. Here we provide a thorough description, over an 11-year period, of an MDR-TB outbreak that emerged and expanded in an HIV-negative context, Northern Tunisia...
2016: PloS One
Loukia Aketi, Zacharie Kashongwe, Christian Kinsiona, Serge Bisuta Fueza, Jack Kokolomami, Grace Bolie, Paul Lumbala, Joseph Shiku Diayisu
Childhood tuberculosis (TB) is a diagnostic challenge in developing countries, and patient outcome can be influenced by certain factors. We report the disease course, clinical profile and factors associated with treatment outcome in a tertiary facility of Kinshasa. Documentary and analytical studies were conducted using clinical and exploratory data for children aged up to 15 years who were admitted to the University Clinics of Kinshasa for TB. Data are presented as frequencies and averages, and binary and logistic regression analyses were performed...
2016: PloS One
Abiola O Olaleye, Andy K Beke
BACKGROUND: A retrospective cohort study was carried out to compare the survival between smear-positive patients and smear-negative multidrug resistant tuberculosis (MDR-TB) patients hospitalised in a specialised TB hospital in Witbank, South Africa. METHODS: A review of medical records of MDR-TB patients treated from 2001 to 2010 was carried out. Survival time was measured from a patient's date of hospitalisation to the date when the patient died, was last treated at the hospital or the end of the study (whichever came first)...
2016: Infectious Diseases
Mohsen A Gadallah, Alaa Mokhtar, Mervat Rady, Essam El-Moghazy, Magdy Fawzy, Sahar Khalil Kandil
BACKGROUND/PURPOSE: Multidrug-resistant tuberculosis (MDR-TB) represents 5% of TB cases globally. In Egypt, it represents 11.4% of TB cases (2.2% of new and 38.2% of previously treated). Our objectives were to evaluate the treatment outcomes and determine the associated prognostic factors among the first national treatment cohort of MDR-TB from 2006 to 2010. METHODS: All patients diagnosed with MDR-TB from July 2006 to December 2010 who were admitted to Abbassia Chest Hospital, the first Egyptian national center established for MDR-TB treatment, were included...
December 13, 2015: Journal of the Formosan Medical Association, Taiwan Yi Zhi
Daniel Meressa, Rocío M Hurtado, Jason R Andrews, Ermias Diro, Kassim Abato, Tewodros Daniel, Paritosh Prasad, Rebekah Prasad, Bekele Fekade, Yared Tedla, Hanan Yusuf, Melaku Tadesse, Dawit Tefera, Abraham Ashenafi, Girma Desta, Getachew Aderaye, Kristian Olson, Sok Thim, Anne E Goldfeld
BACKGROUND: In Africa, fewer than half of patients receiving therapy for multidrug-resistant TB (MDR TB) are successfully treated, with poor outcomes reported for HIV-coinfected patients. METHODS: A standardised second-line drug (SLD) regimen was used in a non-governmental organisation-Ministry of Health (NGO-MOH) collaborative community and hospital-based programme in Ethiopia that included intensive side effect monitoring, adherence strategies and nutritional supplementation...
December 2015: Thorax
Yanni Sun, David Harley, Hassan Vally, Adrian Sleigh
BACKGROUND: We conducted a cohort study to compare the characteristics of MDR-TB with non-MDR-TB patients and to measure long term (9-year) mortality rate and determine factors associated with death in China. METHODS: We reviewed the medical records of 250 TB cases from a 2001 survey to compare 100 MDR-TB patients with 150 non-MDR-TB patients who were treated in 2001-2002. Baseline attributes extracted from the records were compared between the two cohorts and long-term mortality and risk factors were determined at nine-year follow-up in 2010...
2015: BMC Public Health
N Ahmad, A Javaid, A Basit, A K Afridi, M A Khan, I Ahmad, S A S Sulaiman, A H Khan
SETTINGS: Although Pakistan has a high burden of multidrug-resistant tuberculosis (MDR-TB), little is known about the management and treatment outcomes of MDR-TB patients in Pakistan. OBJECTIVE: To evaluate management and predictors of unsuccessful treatment outcomes among MDR-TB patients. METHODS: In this observational cohort study, 196 MDR-TB patients enrolled at the Programmatic Management Unit for drug-resistant TB of Lady Reading Hospital, Peshawar, Pakistan, between 1 January 2012 and 28 February 2013 were included...
September 2015: International Journal of Tuberculosis and Lung Disease
S M Liew, E M Khoo, B K Ho, Y K Lee, O Mimi, M Y Fazlina, R Asmah, W K Lee, M Y Harmy, K Chinna, F D Jiloris
OBJECTIVES: To determine treatment outcomes and associated predictors of all patients registered in 2012 with the Malaysian National Tuberculosis (TB) Surveillance Registry. METHODS: Sociodemographic and clinical data were analysed. Unfavourable outcomes included treatment failure, transferred out and lost to follow-up, treatment defaulters, those not evaluated and all-cause mortality. RESULTS: In total, 21 582 patients were registered. The mean age was 42...
July 2015: International Journal of Tuberculosis and Lung Disease
Teye A Umanah, Jabulani R Ncayiyana, Peter S Nyasulu
BACKGROUND: The global incidence of multidrug-resistant tuberculosis (MDR-TB) is rising, especially among HIV infected patients, despite intervention programs. Limited data are available on outcomes of MDR-TB treatment, specifically in a cohort of HIV co-infected patients in sub-Saharan Africa. The objective of this study was to determine the predictors of cure among MDR-TB HIV co-infected patients. METHODS: A retrospective review of 1200 medical records of HIV co-infected MDR-TB patients was performed at Sizwe Tropical Disease Hospital, Johannesburg covering the period 2007 to 2010...
May 2015: Transactions of the Royal Society of Tropical Medicine and Hygiene
Kalpesh Jain, Mira Desai, Rajesh Solanki, Ram Kumar Dikshit
OBJECTIVE: To evaluate the treatment outcome of second line drugs used in directly observed treatment, short-course (DOTS)-Plus regimen under Revised National Tuberculosis Control Program (RNTCP). MATERIALS AND METHODS: A prospective, observational study was carried out on multidrug resistant tuberculosis (MDR-TB) patients enrolled for DOTS-Plus regimen at TB and Chest Disease Department from January to December 2009. Demographic details, symptoms, sputum examination and adverse drug reactions were recorded in a case record form...
April 2014: Journal of Pharmacology & Pharmacotherapeutics
Samuel Om Manda, Lieketseng J Masenyetse, Joey L Lancaster, Martie L van der Walt
BACKGROUND: Even though highly effective drugs are available in South Africa, multidrug resistant tuberculosis (MDR-TB) patients with HIV infection have higher mortality compared to HIV-uninfected MDR-TB patients. This trend has been observed in similar countries with high HIV prevalence. This study sought to determine excess mortality attributable to HIV among MDR-TB patients in South Africa using relative survival methods. METHODS: Data available were from a cohort of 2079 MDR-TB patients enrolled in a Standardized Programmatic Management of MDR-TB from 2000 to 2004 in South Africa...
July 2, 2013: Journal of AIDS & Clinical Research
Carole D Mitnick, Molly F Franke, Michael L Rich, Felix A Alcantara Viru, Sasha C Appleton, Sidney S Atwood, Jaime N Bayona, Cesar A Bonilla, Katiuska Chalco, Hamish S F Fraser, Jennifer J Furin, Dalia Guerra, Rocio M Hurtado, Keith Joseph, Karim Llaro, Lorena Mestanza, Joia S Mukherjee, Maribel Muñoz, Eda Palacios, Epifanio Sanchez, Kwonjune J Seung, Sonya S Shin, Alexander Sloutsky, Arielle W Tolman, Mercedes C Becerra
RATIONALE: A better understanding of the composition of optimal treatment regimens for multidrug-resistant tuberculosis (MDR-TB) is essential for expanding universal access to effective treatment and for developing new therapies for MDR-TB. Analysis of observational data may inform the definition of an optimized regimen. OBJECTIVES: This study assessed the impact of an aggressive regimen-one containing at least five likely effective drugs, including a fluoroquinolone and injectable-on treatment outcomes in a large MDR-TB patient cohort...
2013: PloS One
Hind Satti, Megan M McLaughlin, Bethany Hedt-Gauthier, Sidney S Atwood, David B Omotayo, Likhapha Ntlamelle, Kwonjune J Seung
BACKGROUND: Although the importance of concurrent treatment for multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection has been increasingly recognized, there have been few studies reporting outcomes of MDR-TB and HIV co-treatment. We report final outcomes of comprehensive, integrated MDR-TB and HIV treatment in Lesotho and examine factors associated with death or treatment failure. METHODS: We reviewed clinical charts of all adult patients who initiated MDR-TB treatment in Lesotho between January 2008 and September 2009...
2012: PloS One
Ekaterina V Kurbatova, Allison Taylor, Victoria M Gammino, Jaime Bayona, Mercedes Becerra, Manfred Danilovitz, Dennis Falzon, Irina Gelmanova, Salmaan Keshavjee, Vaira Leimane, Carole D Mitnick, Ma Imelda Quelapio, Vija Riekstina, Piret Viiklepp, Matteo Zignol, J Peter Cegielski
The Objective of this analysis was to identify predictors of death, failure, and default among MDR-TB patients treated with second-line drugs in DOTS-plus projects in Estonia, Latvia, Philippines, Russia, and Peru, 2000-2004. Risk ratios (RR) with 95% confidence intervals (CI) were calculated using multivariable regression. Of 1768 patients, treatment outcomes were: cure/completed - 1156 (65%), died - 200 (11%), default - 241 (14%), failure - 118 (7%). Independent predictors of death included: age>45 years (RR = 1...
September 2012: Tuberculosis
Guang Xue He, Yan Guang Xie, Li Xia Wang, Martien W Borgdorff, Marieke J van der Werf, Ji Huan Fan, Xing Lu Yan, Fa Bin Li, Xue Zhi Zhang, Yan Lin Zhao, Susan van den Hof
BACKGROUND: In 2004, an anti-tuberculosis (TB) drug resistance survey in Heilongjiang province, China, enrolled 1574 (79%) new and 421 (21%) retreatment patients. Multi-drug resistant (MDR) TB was detected in 7.2% of new and 30.4% of retreatment patients. All received treatment with standardized first-line drug (FLD) regimens. METHODOLOGY/PRINCIPAL FINDINGS: We report treatment outcomes of the 2004 cohort, and long-term outcomes as assessed in the second half of 2008...
2010: PloS One
K Kliiman, A Altraja
OBJECTIVE: To identify risk factors for default from pulmonary tuberculosis (TB) treatment and to assess mortality associated with default in Estonia. DESIGN: All patients with culture-confirmed pulmonary TB who started treatment during 2003-2005 were included in a retrospective cohort study. RESULTS: In 1107 eligible patients, the treatment success rate was 81.5% and the default rate 9.4% (respectively 60.4% and 17.0% in multidrug-resistant TB [MDR-TB])...
April 2010: International Journal of Tuberculosis and Lung Disease
Holly A Anger, Felicia Dworkin, Saarika Sharma, Sonal S Munsiff, Diana M Nilsen, Shama D Ahuja
UNLABELLED: Rationale Linezolid may be effective for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB); however, serious adverse events are common and there is little information on the management of these toxicities. METHODS: We retrospectively reviewed public health and medical records of 16 MDR TB patients, including 10 patients with XDR TB, who were treated with linezolid in New York City between January 2000 and December 2006, to determine treatment outcomes and describe the incidence, management and predictors of adverse events...
April 2010: Journal of Antimicrobial Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"